This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
Injected once daily subcutaneously (s.c., under the skin)
Injected once daily subcutaneously (s.c., under the skin)
CABA, Argentina
Córdoba, Argentina
Mar del Plata, Argentina
Rosario, Argentina
Zárate, Argentina